Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.71 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | WDR5 | P61964 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28775961 | 0.89 | ALDH1A1 (0.56) | ALDH1A1MCL1POLBMAPTLMNA | |
| SCHEMBL12005301 | 0.87 | ALDH1A1 (0.55) | ALDH1A1MCL1POLBMAPTLMNA | |
| SCHEMBL30879347 | 0.87 | ALDH1A1 (0.55) | ALDH1A1MCL1POLBMAPTLMNA | |
| SCHEMBL28032257 | 0.87 | ALDH1A1 (0.76) | ALDH1A1POLBMAPTLMNAGAA | |
| SCHEMBL16824845 | 0.85 | ALDH1A1 (0.74) | ALDH1A1POLBMAPTLMNAGAA | |
| SCHEMBL6257607 | 0.85 | ALDH1A1 (0.74) | ALDH1A1POLBMAPTLMNAGAA | |
| SCHEMBL16824862 | 0.85 | ALDH1A1 (0.66) | ALDH1A1MCL1POLBMAPTLMNA | |
| SCHEMBL16824854 | 0.85 | MAPT (0.67) | ALDH1A1MAPTLMNAGAAKMT2A | |
| SCHEMBL16824985 | 0.84 | ALDH1A1 (0.69) | ALDH1A1MCL1POLBMAPTLMNA | |
| SCHEMBL16824993 | 0.84 | LMNA (0.67) | ALDH1A1MCL1POLBMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| EP-4610262-A1 | MACROCYCLIC COMPOUND AS CDK9 INHIBITOR AND USE THEREOF | Artivila Biopharma (CN) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| CN-115838375-A | Pyrimido-dihydro-pyrazolone derivative, pharmaceutically acceptable salt thereof, and preparation method and application thereof | 优领医药科技(香港)有限公司 | 2023-03-24 | — | — | CN | disclosed |
| CN-106415244-B | Reactive marker compounds and uses thereof | 中央研究院 | 2020-04-24 | — | — | CN | disclosed |
| US-10119972-B2 | Reactive labelling compounds and uses thereof | ACADEMIA SINICA (TW) | 2018-11-06 | — | — | US | disclosed |
| EP-2334301-B1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK SERONO SA (CH) | 2018-02-14 | — | — | EP | disclosed |
| US-20180011104-A1 | REACTIVE LABELLING COMPOUNDS AND USES THEREOF | ACADEMIA SINICA (TW) | 2018-01-11 | — | — | US | disclosed |
| US-9759726-B2 | Reactive labelling compounds and uses thereof | ACADEMIA SINICA (TW) | 2017-09-12 | — | — | US | disclosed |
| WO-2015148915-A9 | REACTIVE LABELLING COMPOUNDS AND USES THEREOF | ACADEMIA SINICA (TW) | 2016-12-22 | — | — | WO | disclosed |
| US-20150309041-A1 | REACTIVE LABELLING COMPOUNDS AND USES THEREOF | ACADEMIA SINICA (TW) | 2015-10-29 | — | — | US | disclosed |
| WO-2015148915-A1 | REACTIVE LABELLING COMPOUNDS AND USES THEREOF | ACADEMIA SINICA (TW) | 2015-10-01 | — | — | WO | disclosed |
| US-8815872-B2 | Macrocyclics pyrimidines as aurora kinase inhibitors | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20110294801-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| CN-102143750-A | Macrocyclics pyrimidines as aurora kinase inhibitors | MERCK PATENT GMBH | 2011-08-03 | — | — | CN | disclosed |
| EP-2334301-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | Merck Serono SA (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010028116-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-03-11 | — | — | WO | disclosed |
| WO-2008140419-A2 | PYRIDYL SUBSTITUTED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008140419-A2 | PYRIDYL SUBSTITUTED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | ALDH1A1 999/4885MCL1 282/4885POLB 458/4885 |
| US-20150309041-A1 | REACTIVE LABELLING COMPOUNDS AND USES THEREOF | MPI, AADAC, PAICS | ALDH1A1 364/4885MCL1 1284/4885POLB 3628/4885 |
| US-20180011104-A1 | REACTIVE LABELLING COMPOUNDS AND USES THEREOF | MPI, AADAC, PAICS | ALDH1A1 273/4885MCL1 1149/4885POLB 3725/4885 |
| US-10119972-B2 | Reactive labelling compounds and uses thereof | MPI, AADAC, PAICS | ALDH1A1 273/4885MCL1 1149/4885POLB 3725/4885 |
| US-20110294801-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | AURKC, AURKA, AURKB | ALDH1A1 4424/4885MCL1 415/4885POLB 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.